AI assistant
Sending…
Rua Bioscience Limited — Share Issue/Capital Change 2025
Sep 12, 2025
66262_rns_2025-09-12_3d28f87f-5ca8-47f1-88d0-ca470c76ab10.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Capital Change Notice
==> picture [78 x 33] intentionally omitted <==
| Section 1: Issuer information | |
|---|---|
| Name of issuer | Rua Bioscience Limited |
| NZX ticker code | RUA |
| Class of financial product | Ordinary shares |
| ISIN (If unknown, check on NZX website) | NZRUAE0004S1 |
| Currency | NZ$ |
| Section 2: Capital change details | |
| Number issued/acquired/redeemed | 335,472 warrants |
| Nominal value (if any) | N/A |
| Issue/acquisition/redemption price per security | $0.015 |
| Nature of the payment (for example, cash or otherconsideration) | No consideration is payable forthe warrants. Cashconsideration of $0.015 pershare is payable on exercise ofthe warrants |
| Amount paid up (if not in full) | Paid in full on exercise of thewarrant |
| Percentage of total class of Financial Productsissued/acquired/redeemed/ (calculated on the number ofFinancial Products of the Class, excluding any Treasury Stock,in existence)1 | Rua currently has 239,114,678ordinary shares on issue and5,591,201 warrants on issue.This issue of warrantsrepresents 0.14% of the totalordinary shares plus warrantson issue (being the percentageshould all warrants vest and beexercised). |
| For an issue of Convertible Financial Products or Options, theprincipal terms of Conversion (for example the Conversionprice and Conversion date and the ranking of the FinancialProduct in relation to other Classes of Financial Product) or theOption (for example, the exercise price and exercise date) | Vesting will occur 12 monthsfollowing theIssue/Commencement Dateafter which the warrants areable to be converted/exercisedto ordinary shares up to theMaturity Date which is 3 yearsfollowing theIssue/Commencement Date. |
| Reason for issue/acquisition/redemption and specific authorityfor issue/acquisition/redemption/ (the reason for change mustbe identified here) | Issue of warrants as per BoardResolution regarding debtfacility arrangement. |
| Total number of Financial Products of the Class after theissue/acquisition/redemption/Conversion (excluding TreasuryStock) and the total number of Financial Products of the Classheld as Treasury Stock after the issue/acquisition/redemption. | Total ordinary shares on issue:239,114,678 ordinary sharesTotal warrants on issue:5,926,673 warrants |
1 The percentage is to be calculated immediately before the issue, acquisition, redemption or Conversion.
| In the case of an acquisition of shares, whether those sharesare to be held as treasury stock | N/A |
|---|---|
| Specific authority for the issue, acquisition, or redemption,including a reference to the rule pursuant to which the issue,acquisition, or redemption is made | Board resolution and ListingRule 4.5.1 |
| Terms or details of the issue, acquisition, or redemption (forexample: restrictions, escrow arrangements) | The warrants are issued aspart of a Debt Facilityarrangement.Vesting will occur 12 monthsfollowing theIssue/Commencement Dateafter which the warrants areable to be converted toordinary shares up to theMaturity Date which is 3 yearsfollowing theIssue/Commencement Date.New ordinary shares issuedupon exercise of the warrantswill rank equally in all respectswith the ordinary sharesalready on issue. |
| Date of issue/acquisition/redemption | 11/09/2025 |
| Section 3: Authority for this announcement and contact person | |
| Name of person authorised to make this announcement | Paul Naske |
| Contact person for this announcement | Paul Naske |
| Contact phone number | 021 445 154 |
| Contact email address | [email protected] |
| Date of release through MAP | 12/09/2025 |
More from Rua Bioscience Limited
Director's Dealing
2026
May 22
Share Issue/Capital Change
2026
May 21
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 12
Interim / Quarterly Report
2026
Feb 26
Director's Dealing
2026
Jan 20
Major Shareholding Notification
2026
Jan 20
Director's Dealing
2026
Jan 19
Director's Dealing
2026
Jan 19
Major Shareholding Notification
2026
Jan 15